WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today reported financial results for the fourth quarter and fiscal year ended December 31, 2008. Total revenues for the fourth quarter of 2008 were $26.4 million, compared to $25.3 million in the fourth quarter of 2007. Revenue from the cardiovascular drug ANTARA® (fenofibrate) capsules increased to $21.2 million in the fourth quarter of 2008, from $19.3 million in the fourth quarter of 2007. Revenues from the antibiotic FACTIVE® (gemifloxacin mesylate) tablets decreased to $5.2 million in the fourth quarter of 2008, from $5.9 million in the fourth quarter of 2007.
